Stock comparison
IDEXX Laboratories
Bio-Techne
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.06B
Sector
Healthcare
TECH
Bio-Techne
Market cap
$7.55B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | TECH | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 55C | IDXX |
| Benjamin Graham | 80A | 89A | TECH |
| Philip Fisher | 75B | 50C | IDXX |
| Peter Lynch | 71B | 24F | IDXX |
| Joel Greenblatt | 83C | 50D | IDXX |
| Charlie Munger | 87A | 45D | IDXX |
| Terry Smith | 84A | 44D | IDXX |
Side-by-side metrics
| Metric | IDXX | TECH |
|---|---|---|
| Market cap | $44.06B | $7.55B |
| P/E (TTM) | 39.0x | 61.6x |
| EV/EBIT | 31.6x | 67.1x |
| ROIC (TTM) | 40.66% | 4.75% |
| Gross margin | 62.05% | 64.96% |
| Net margin | 24.63% | 9.05% |
| Revenue CAGR 5y | 7.56% | 6.98% |
| EPS CAGR 5y | 10.79% | -15.23% |
| Debt / Equity | 0.7x | 0.1x |
| Dividend yield | 0.0% | 0.74% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- EPS CAGR 5y10.79%vs -15.23%+171%
- ROIC (TTM)40.66%vs 4.75%+88%
- Market cap$44.06Bvs $7.55B+83%
- Net margin24.63%vs 9.05%+63%
TECH leads on
- Dividend yield0.74%vs 0.0%+100%
- Debt / Equity0.1xvs 0.7x+80%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.